Evidence map›Paper›PMID 28130226›Full record

ArticleCancer research2017

Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model.

Wei Du, Rebecca Goldstein, Yanwen Jiang, Omar Aly, Leandro Cerchietti, Ari Melnick, Olivier Elemento

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Computational modelling of aggressive B-cell lymphoma.Biochemical Society transactions · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Translational medicine in the Age of Big Data.Briefings in bioinformatics · 2019
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 2 countries.

Wei DuInstitute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.
Rebecca GoldsteinHematology/Oncology Division, Department of Medicine, Weill Cornell Medicine, New York, New York.
Yanwen JiangInstitute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.
Omar AlyInstitute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.
Leandro CerchiettiHematology/Oncology Division, Department of Medicine, Weill Cornell Medicine, New York, New York.
Ari MelnickHematology/Oncology Division, Department of Medicine, Weill Cornell Medicine, New York, New York.
Olivier ElementoInstitute for Computational Biomedicine, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York. ole2001@med.cornell.edu.
Cornell University · US

Funding

Molecular Targeting of Diffuse Large B-cell LymphomaR01CA143032 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2010 to 2014
$2.8M
The identification and validation of mechanisms and biomarkers for relapse in diffuse large B-cell lymphoma (Administrative Supplement)R01CA194547 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ELEMENTO, OLIVIER, TAM, WAYNE · 2015 to 2019
$2.6M
Transcriptional silencing by the BCL6 oncoproteinR01CA104348 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MELNICK, ARI M. · 2004 to 2014
$2.6M
The joint WCM-NYGC Center for Functional and Clinical Interpretation of Tumor ProfilesU24CA210989 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI ELEMENTO, OLIVIER, ZODY, MICHAEL C · 2016 to 2020
$2.4M
NCI NIH HHS R01 CA104348NCI NIH HHS R01 CA143032NCI NIH HHS R01 CA194547NCI NIH HHS U24 CA210989
6 · The paper itself

Abstract

The complexity of cancer signaling networks limits the efficacy of most single-agent treatments and brings about challenges in identifying effective combinatorial therapies. In this study, we used chronic active B-cell receptor (BCR) signaling in diffuse large B-cell lymphoma as a model system to establish a computational framework to optimize combinatorial therapy

Indexed as

Models, BiologicalCell Growth ProcessesCombined Modality TherapyHumansLymphoma, Large B-Cell, DiffuseMAP Kinase Signaling SystemNF-kappa BProtein Interaction MapsProto-Oncogene Proteins c-aktReceptors, Antigen, B-CellSignal TransductionNF-kappa BProto-Oncogene Proteins c-aktReceptors, Antigen, B-Cell

Identifiers

PMID28130226
PMCPMC5392381
OpenAlexW2581049015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.